Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03429920 · ClinicalTrials.gov registry record · NA

Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors

A NA study of Inflammation and Heart Diseases, sponsored by Loma Linda University.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT03429920: Completed NA study of Inflammation and Heart Diseases, sponsored by Loma Linda University.

NCT03429920 is a NA study of Inflammation and Heart Diseases that has completed, run by Loma Linda University. The registered enrollment target is 28 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03429920, a NA study of Inflammation and Heart Diseases, has completed, sponsored by Loma Linda University.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This research study will test the effects of Q CAN PLUS powder on serum lipids, selected inflammatory and oxidative parameters and genome-wide methylation

Primary Outcome

This is a composite measurement which will measure the change in the levels of serum Low Density Cholesterol, High Density Cholesterol, ApoLipoprotein A and B, APO E Allele genetic typing and triglycerides before the ingestion of QCAN PLUS powder and at 7 months after ingestion of Q CAN PLUS powder.

Conditions Studied

Inflammation Heart Diseases Cardiovascular Risk Factor

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Q CAN PLUS

Study Locations (1)

California

  • Loma Linda University - Loma Linda

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2018-09-23
Est. Completion 2019-08-01
Phase NA
Loma Linda University

237 total trials

What the finished NCT03429920 record still lists

NCT03429920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03429920 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03429920 about?

NCT03429920 is a clinical study titled "Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors". This research study will test the effects of Q CAN PLUS powder on serum lipids, selected inflammatory and oxidative parameters and genome-wide methylation

What is the current status of trial NCT03429920?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2018-09-23. Estimated completion is 2019-08-01.

What conditions does trial NCT03429920 study?

This clinical trial studies the following conditions: Inflammation, Heart Diseases, Cardiovascular Risk Factor.

What interventions are being tested in trial NCT03429920?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Q CAN PLUS (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03429920?

This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03429920 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03429920's enrollment target sits among peer trials

28 108th of 132 higher than 22 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03429920, the US trial registry maintained by the National Library of Medicine. NCT03429920 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.